A new study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center may help explain why certain liver ...

The Mount Sinai researchers administered two rounds of the immunotherapy agent, cemiplimab, to 21 early-stage liver cancer patients three weeks prior to surgery.

Oct. 8 -- WEDNESDAY, Oct. 7 (HealthDay News) -- A short strand of RNA (microRNA) may help doctors identify liver cancer patients who would benefit from treatment with interferon, say U.S. and ...

In a trial published last year, researchers found that for patients with advanced liver cancer, the combination worked better than a drug that had been the standard of care for 13 years.

When delivering a liver cancer diagnosis, Dr. Thomas Marron pulls no punches: "Liver cancer is one of the deadliest cancers," he tells patients. Jeffrey Foster heard a similar message loud and ...

Advanced Liver Cancer Patients Live Longer By Taking Anti-cancer Drug Sorafenib. ScienceDaily. Retrieved June 4, 2025 from www.sciencedaily.com / releases / 2008 / 07 / 080723171837.htm.

Up to 100,000 Americans will be diagnosed with colon cancer this year alone. In almost half of these patients, the cancer will spread to the liver--and for many, this will prove deadly.The most ...

An interdisciplinary research team has demonstrated a durable and lasting response to a novel treatment—combined locoregional therapy and immunotherapy (LRT-IO)—for advanced liver cancer patients.

Patients with the most common type of liver cancer who are taking the chemotherapy drug sorafenib can begin their treatment with a lower dose than is currently considered standard, and it will not ...

Fatty liver disease affects more than 1 in 3 adults and often has no symptoms. A new drug developed with Tulane researchers ...

Patients had a variety of cancer types, including non-small cell lung cancer, melanoma, urothelial cancer and renal cell cancer, which had spread to different organs, including the liver and lungs.

Research methods and findings. The HKUMed research team closely monitored 63 patients with locally advanced unresectable liver cancer who had been treated with the LRT-IO approach between January ...